PMID- 12620152
OWN - NLM
STAT- MEDLINE
DCOM- 20050823
LR  - 20191106
IS  - 1526-8209 (Print)
IS  - 1526-8209 (Linking)
VI  - 3 Suppl 4
DP  - 2003 Feb
TI  - The role of cancer vaccines following autologous stem cell rescue in breast and 
      ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
PG  - S144-51
AB  - The success of high-dose chemotherapy followed by autologous stem-cell rescue as 
      treatment for breast and ovarian cancer is limited by a high incidence of 
      relapse. After autologous transplantation, patients are likely to have a low 
      tumor burden and thus would be more likely to respond immunologically to a cancer 
      vaccine. Sialyl-Tn (STn) is a carbohydrate associated with the MUC1 mucin on 
      breast and ovarian cancer and is an ideal candidate for vaccine immunotherapy. 
      Sialyl-Tn-keyhole limpet hemocyanin (STn-KLH) vaccine (Theratope) incorporates a 
      synthetic STn antigen that mimics the unique tumor-associated STn carbohydrate 
      and is designed to stimulate tumor antigen-specific immune responses in patients 
      with mucin-expressing tumors. Between 1995 and 2000, 70 patients (16 with stage 
      II/III breast cancer, 17 with stage III/IV ovarian cancer, and 37 with stage IV 
      breast cancer) were treated with 2 different formulations of STn-KLH. Toxicity, 
      outcome, and immune response data are reported. STn-KLH was well-tolerated with 
      minimal toxicity. The most common side effects were indurations and erythema at 
      the sites of injections. Humoral and cellular responses were elicited in the 
      majority of patients. Overall, these data indicate that post-autologous 
      transplant patients are able to mount an effective immune response to vaccine 
      immunotherapy with minimal side effects, and that vaccine immunotherapy may be a 
      useful addition to high-dose chemotherapy regimens.
FAU - Holmberg, Leona A
AU  - Holmberg LA
AD  - Department of Medicine, University of Washington School of Medicine, and Clinical 
      Research Division, Fred Hutchinson Cancer Research Center, Seattle 98109-1024, 
      USA. lholmber@fhcrc.org
FAU - Oparin, Dimitri V
AU  - Oparin DV
FAU - Gooley, Ted
AU  - Gooley T
FAU - Sandmaier, Brenda M
AU  - Sandmaier BM
LA  - eng
GR  - CA66186/CA/NCI NIH HHS/United States
GR  - CA67112/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Clinical Trial, Phase II
PT  - Clinical Trial, Phase III
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Antigens, Tumor-Associated, Carbohydrate)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Mucin-1)
RN  - 0 (sialyl-Tn antigen-keyhole-limpet hemocyanin conjugate)
RN  - 9013-72-3 (Hemocyanins)
SB  - IM
MH  - Antigens, Tumor-Associated, Carbohydrate/*immunology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/*immunology/*therapy
MH  - Cancer Vaccines/administration & dosage/adverse effects/*therapeutic use
MH  - Cell Proliferation
MH  - Disease Progression
MH  - Female
MH  - Hemocyanins/*immunology/*therapeutic use
MH  - Humans
MH  - Mucin-1/immunology
MH  - Ovarian Neoplasms/*immunology/*therapy
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Survival Analysis
MH  - Transplantation, Autologous
MH  - Treatment Outcome
EDAT- 2003/03/07 04:00
MHDA- 2005/08/24 09:00
CRDT- 2003/03/07 04:00
PHST- 2003/03/07 04:00 [pubmed]
PHST- 2005/08/24 09:00 [medline]
PHST- 2003/03/07 04:00 [entrez]
AID - S1526-8209(11)70330-5 [pii]
AID - 10.3816/cbc.2003.s.004 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2003 Feb;3 Suppl 4:S144-51. doi: 10.3816/cbc.2003.s.004.